CONTENTS:
- GLP-1R agonist medications for addiction treatment [Editorial]. Volkow N.D., Xu R., p. 198-200.
- Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis? [Addiction opinion and debate]. Andrews C.M., Hall W., Humphreys K., Marsden J., p. 201-206.
- A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs. Bogenschutz M.P., p. 207-208.
- How psychedelics legalization debates could differ from cannabis. Kilmer B., p. 209-210.
- Do not conflate debates on regulating therapeutic use of psychotropic substances with those on the legalization of their non-therapeutic use. Zullino D., p. 211-212.
- Disentangling debate about therapeutic and recreational use of psychedelics. Andrews C., Hall W., Humphreys K., Marsden J., p. 213-214.
- Understanding the mechanisms of change in social norms around tobacco use: A systematic review and meta-analysis of interventions. Lahiri S., Bingenheimer J.B., Evans W.D., Wang Y., Cislaghi B., Dubey P., et al., p. 215-235.
- The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Qeadan F., McCunn A., Tingey B., p. 236-250.
- Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal. Schepis T.S., p. 251-252.
- Public perceptions of opioid misuse recovery and related resources in a nationally representative sample of United States adults. Golan O., Kresovich A., Drymon C., Ducharme L., Flanagan Balawajder E., Borowiecki M., et al., p. 253-265.
- Early detection and prediction of non-fatal drug-related incidents and fatal overdose outbreaks using the Farrington algorithm. Patton T., Trillo-Park S., Swift B., Borquez A., p. 266-275.
- Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011-2020: A national retrospective cohort study. Fraser R., Yeung A., Glancy M., Hickman M., Jones H.E., Priyadarshi S., et al., p. 276-284.
- Differences in heroin overdose risk associated with the unregulated drug market: Insights from a supervised injecting facility in Melbourne, Australia. Stam N.C., Furler J., Hiley S., Schumann J.L., p. 285-292.
- Commentary on Stam et al.: The substantial and dynamic contribution of opioid potency to total overdose risk. Coffin P.O., p. 293-295.
- Predictors of emergency medical transport refusal following opioid overdose in Washington, DC. Turley B., Zamore K., Holman R.P., p. 296-305.
- Drug overdose deaths among homeless veterans in the United States Department of Veterans Affairs healthcare system. Tsai J., Szymkowiak D., Beydoun H.A., p. 306-315.
- Improving racial/ethnic health equity and naloxone access among people at risk for opioid overdose: A simulation modeling analysis of community-based naloxone distribution strategies in Massachusetts, United States. Zang X., Skinner A., Li Z., Shaw L.C., Behrends C.N., Chatterjee A., et al., p. 316-326.
- Use and perceptions of involuntary civil commitment among post-overdose outreach staff in Massachusetts, United States: A mixed-methods study. Cummins E.R., Walley A.Y., Xuan Z., Yan S., Schoenberger S.F., Formica S.W., et al., p. 327-334.
- Post-legalization shifts in cannabis use among young adults in Georgia - A nationally representative study. Nadareishvili I., Rao S.R., Otiashvili D., Gnatienko N., Samet J.H., Lunze K., et al., p. 335-346.
- Parental alcohol use and the level of child protection response in Australia (2012-21). Smit K., Rintala J., Riordan B., Lee K., Laslett A.M., p. 347-357.
- Sibling socialization of alcohol use during adolescence: An integrated model of sibling influence processes. Whiteman S.D., Zhou W., Serang S., Maiya S., Kelly B.C., Mustillo S.A., et al., p. 358-367.
- Cost-utility analysis of provision of e-cigarette starter kits for smoking cessation in emergency departments: An economic evaluation of a randomized controlled trial. Li J., Wu Q., Parrott S., Pope I., Clark L.V., Clark A., et al., p. 368-379.
- Rare but relevant: Cannabinoid hyperemesis syndrome. Stjepanovic D., Kirkman J., Hall W., p. 380-384.
- Combating opioid misuse in Nigeria: A comprehensive strategy for public health and social stability. Oladapo R., Oladapo M., p. 385-386.
- The rise of novel, semi-synthetic 7-hydroxymitragnine products. Smith K.E., Boyer E.W., Grundmann O., McCurdy C.R., Sharma A., p. 387-388.